We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    IND 15069
Previous Study | Return to List | Next Study

Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia (CLI)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01867190
First Posted: June 3, 2013
Last Update Posted: April 22, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Lifecells, LLC.
May 29, 2013
June 3, 2013
April 22, 2016
May 2013
March 2016   (Final data collection date for primary outcome measure)
To assess the efficacy and safety of intra-arterial infusion and intramuscular injection of ASCT01 on the combined primary endpoint of major amputation (above the ankle) or persisting critical limb ischemia (no clinical or perfusion improvement). [ Time Frame: primary outcome measured at 3 months ]
The primary outcome variable is "treatment failure" defined as major amputation (above the ankle) of the affected limb within 3 months or an unchanged critical limb ischemia of the affected limb after 3 months defined as less than 15% change in tcPO2 or ABI or absolute ankle pressure.
Same as current
Complete list of historical versions of study NCT01867190 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia
An Open-label Single Arm Phase 2 Proof of Concept Study to Assess the Efficacy and Safety of ASCT01 in Patients With Critical Limb Ischemia
This study will assess the safety and efficacy of intra-arterial infusion and intramuscular injection of an autologous, bone marrow-derived stem cell preparation (ASCT01) versus placebo in patients with critical limb ischemia who have exhausted all medical and surgical therapeutic options. The safety and tolerability will be evaluated by regular monitoring of the general physical condition, vital signs, and the occurrence of AE and SAE, respectively. Furthermore, the standard biochemical and blood variables (red and white blood cell counts, Hb, Ht, platelets, sodium, potassium, chloride, calcium, phosphor, ASAT, ALAT, bilirubin, total protein, albumin, AP, cholesterol (LDL,HDL), triglycerides, urea and creatinine, immunoglobulins, HBA1c, C-peptide) will be checked before the treatment as well as 30 and 90 days after the treatment.
Efficacy will be determined by number of collateral arteries as assessed magnetic resonance angiography at baseline and again at 3 months, rate of major amputation (above the ankle) of the affected limb within 3 months or an unchanged critical limb ischemia of the affected limb after 3 months defined as less than 15% change in tcPO2 or ABI or absolute ankle pressure.Efficacy endpoint is at 3 months. Clinical endpoints and safety will be measured through 12 months.
Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Critical Limb Ischemia
Biological: ASCT01 (Autologous Stem Cell Transplantation)
Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
Experimental: ASCT01
CD34+ and CD45+ cells in ASCT01 preparation
Intervention: Biological: ASCT01 (Autologous Stem Cell Transplantation)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
March 2016
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male and Female patients in the age group of 18-80yrs.
  2. Established CLI (confirmed by Rutherford 4 to 5) with angiographic evidence of significant infra-inguinal arterial occlusive disease
  3. Ankle Brachial Pressure Index (ABI) ≤ 0.6 or the absolute ankle blood pressure < 60 mm Hg or TcPO2<20 mmHg without tissue loss or TcPO2<40 mmHg if there is tissue loss or alternatively toe Brachial Pressure Index (TBI) less 0.5 or the absolute toe blood pressure less than 50 mm Hg
  4. No surgical or interventional option for revascularization and no response to best standard care delivered as confirmed by a vascular surgeon and/or physician.
  5. No immediate life-threatening complication from CLI which would demand immediate amputation.
  6. Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits.
  7. On optimal medical therapy
  8. If diabetic, HgbA1c <10%

Exclusion Criteria:

  1. Acute life threatening complication of limb ischemia with the need for immediate limb amputation to avoid death or clinical deterioration
  2. Patients with confirmed Rutherford 6 condition with extensive tissue damage
  3. Patients with documented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 6 months.
  4. Patients with a history of severe alcohol or drug abuse within 3 months of screening.
  5. Known bone marrow diseases which preclude transplantation.
  6. End-stage renal failure on regular dialysis treatment. Creatinine ≥2.0 mg/dl
  7. Patients already enrolled in another investigational drug trial or completed within 1month.
  8. Pregnancy.
  9. Patients tested positive for HIV screen1or2, Hepatitis C antibody Hepatitis B surface-antigen, HepatitisBcore Antibody, Syphilis screen
  10. Myocardial infarction / CVA / TIA within the past three months prior to enrollment
  11. Revascularization procedure in target limb within 6 weeks prior to enrollment
  12. Laboratory values as show below*
  13. Currently taking immunosuppressive agents
  14. If diabetic, diagnosis of proliferative retinopathy
  15. Patients with infected ulcers or systemic infections *Laboratory Values: Hemoglobin <10 g/dL Platelet count <100,000/microL ALT >60 U/L AST >60 U/L Bilirubin >1.0 mg/dL INR >1.3 unless on Coumadin and at Investigator discretion APTT >40 second unless on Lovenox or Heparin and at Investigator's discretion
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01867190
IND 15069
Yes
Not Provided
Not Provided
Lifecells, LLC.
Lifecells, LLC.
Not Provided
Study Director: Paul T Sudhakar, MS, Pharm Lifecells, LLC.
Lifecells, LLC.
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP